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REPORTING QUALITY OF DOUBLE-BLIND RANDOMIZED CONTROLLED 
TRIALS AND ITS ASSOCIATION WITH THE FUNDING AGENCY
Singh N, Agrawal R, Dimri S, Ubhadiya BS, Narvilkar P, Bhanderi M
Heron Health Private Limited, Chandigarh, India
OBJECTIVE: To assess the reporting quality of double-blind randomized controlled trials 
(RCTs) published in the New England Journal of Medicine (NEJM) using Jadad scale and 
to examine the relationship between funding source and quality of reporting. METHODS:
Medline database was searched for RCTs. Search was limited to RCTs published in the last
ﬁ ve years in the NEJM and performed on humans. Quality of reporting was assessed using 
the Jadad scale (1 to 5). The analysis was limited only to the double-blind RCTs assessing
drug or vaccine based intervention. RESULTS: A total of 207 double-blind trials out of
489 RCTs were assessed for reporting quality. Median (mean) Jadad score was 4 (3.8). The 
proportion of trials with Jadad score 5 was 20.8% whereas 5.8% trials received a Jadad
score of 2. None of the trials received a Jadad score of 1. Method of randomization and 
concealment of allocation was adequate in 35.3% and 47.8% trials, respectively. Method
of blinding was adequate in 51.2% of trials. A total of 89.4% trials reported details of 
follow-up and reasons for withdrawal. The quality of reporting was good (Jadad score
 3) in 94.2% studies. Year-wise analysis showed that 100%, 91%, 91%, 94% and 96% 
studies were of good reporting quality in the year 2004, 2005, 2006, 2007, and 2008,
respectively. A Jadad score of 5 was received by 41% (9 out of 22) government sponsored
trials as compared to only 14% (15 out of 107) trials sponsored by industry. CONCLU-
SION: There is a scope for further improvement in reporting of method for randomization,
concealment of allocation and method of blinding. Inﬂ uence of funding agency on the 
quality of reporting could be analyzed further.
CANCER – Clinical Outcomes Studies
PCN1
TIME DELAY OF OCCURRENCE OF SECONDARY MALIGNANT TUMORS
AFTER PRIMARY BREAST CANCER IN THE FEMALE POPULATION OF
HUNGARY BETWEEN 2003 AND 2007
Gazdag L1, Boncz I1, Farkasné JE1, Bódis J2, Németh K1, Kornya L1, Vránics I1, Gabara K1, 
Kriszbacher I2
1University of Pécs, Pécs, Hungary, 2University of Pécs, Pecs, Hungary
OBJECTIVES: The purpose of this study was to determine the time delay from the 
diagnosis of primer breast cancer to the appaerance of secondary tumors affecting other
organs in Hungary. METHODS: Data were collected from the nationwide ﬁ nancing 
database of the National Health Insurance Fund Administration (OEP). The subject of 
the observation aimed female patients treated in hospitals with primary breast tumor 
(BNO: C5000-C5090, D0570, D0590) between the period of January 1, 2002 and 
December 31, 2002. We examined the time delay between the diagnosis of primary
breats cancer in 2002 and its secondary malignancies in the following 5 years.
RESULTS: In 2002, a total of 7548 patients were treated in hospitals with malignant
primary breast tumor. Between 2003 and 2007 2870 primary breast tumor patients 
attended in hospitals with tumor disorders affected any other organs. In the following 
ﬁ ve years after the occurrence of primary breast tumors, secondary malignant tumors 
affecting other organs were occurred in 21.32% of the patients. The ﬁ ve most often 
appeared malignant diseases in the examined period were: malignant tumors in the
bones and bone marrow were diagnosed 29.0 months, malignant tumor in the lung
34.4 months, malignant tumor in the lymph gland 20.3 months, malignant tumor of 
the liver 29.7 months and malignant tumor in the brain and dural tumor 32.3 months 
after the occurrence of primary breast tumors. CONCLUSIONS: In the following ﬁ ve 
years other malignant tumors were occurred in one ﬁ fth of the primary breast tumor
patients. For the diagnoses of the ﬁ ve most often secondary tumors 29.1 months, or
2.4 years were needed. In consideration to all occurred secondary tumors in case of 
the whole population this value is on the average 35.2 months or 2.9 years.
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THE FREQUENCY OF OCCURRENCE OF SECONDARY MALIGNANT
TUMORS EVOLVING ON THE FIELD OF PRIMARY BREAST CANCER IN
THE FEMALE POPULATION OF HUNGARY BETWEEN 2003 AND 2007
Gazdag L1, Boncz I1, Farkasné JE1, Bódis J2, Németh K1, Kornya L1, Vránics I1, Gabara K1, 
Kriszbacher I2
1University of Pécs, Pécs, Hungary, 2University of Pécs, Pecs, Hungary
OBJECTIVES: The purpose of this study was to determine the frequency of occurrence 
of secondary tumors affecting other organs in case of patients suffering from tumor
located in any ﬁ elds of the breast. METHODS: Data were collected from the ﬁ nancing 
database of the National Health Insurance Fund Administration (OEP). The subject 
of the observation aimed female patients treated in hospitals with primary breast
tumor (BNO: C5000-C5090, D0570, D0590) between the period of January 1, 2002 
and December 31, 2002. Accordingly we examined the frequency of occurrence of 
secondary tumors evolving after occurrence of the primary tumor in the following 5 
years (2003–2007). RESULTS: In 2002, a total of 10,378 patients (21,418 cases) were 
treated with malignant breast tumor. 2,870 primary breast tumor patients attended in
hospitals with tumor disorders in any organs between 2003 and 2007. The ﬁ rst ﬁ ve
malignant diseases appeared the most often in the examined period were: malignant
tumors in the bones and bone marrow in 298 patients, malignant tumor in the lung
in 212 patients, malignant tumor in the lymph gland in 186 cases, malignant tumor 
of the liver in 182 cases and malignant brain and dural tumor in 151 cases. The fre-
quency of occurrence of these tumors projected on 10,000 primary breast tumors is 
the following: malignant tumors in the bones and bone marrow in 395 patients, 
malignant tumor in the lung in 281 patients, malignant tumor in the lymph gland in 
246 cases, malignant tumor of the liver in 241 cases and malignant brain and dural
tumor in 200 cases. CONCLUSIONS: In the following 5 years of the primary breast
tumor diseases other malignant tumors affecting other organs were evolved in 21.32% 
of the patients. In 26.67% of the patients no secondary tumors were evolved, but the 
primary tumor needed further treatment.
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THE FEASIBILITY AND COST OF EARLY DETECTION OF PROSTATE
CANCER IN GASTROENTEROLOGY UNITS
Shafran-Tikva S1, Lysy J1, Goldin E1, Greenberg D2
1Hadassah University Medical Center, Ein Kerem, Jerusalem, Israel, 2Ben-Gurion University of 
the Negev, Beer-Sheva, Israel
OBJECTIVES: The American Cancer Society suggests that men over the age of 50 
should have their PSA level checked and undergo a rectal examination for early detec-
tion of prostate cancer. However, rectal examinations are infrequently performed by 
family physicians in Israel. Palpitation of the prostate gland can be performed during
routine rectal examination of patients arriving at gastroenterology units for lower 
digestive system examinations and serve as an additional tier in the early detection of 
prostate cancer. We evaluated the cost and feasibility of routine rectal examinations 
for early detection of prostate cancer in a gastroenterology unit, and follow-up by
family physician. METHODS: Our study population included a convenience sample 
of 554 males (age 50–79) arriving at Hadassah Ein-Kerem Medical Center in Israel. 
During the rectal examination, the gastroenterologist estimated the size, structure and
texture of the prostate gland. Patients with suspected pathological results were referred 
to their family physician for further examinations. We assessed the costs of the screen-
ing and follow-up program using the Ministry of Health price list. These costs included 
the costs of family physician and urologist consultations, PSA test, rectal ultrasound,
and biopsy. RESULTS: In 145 of patients (26.1%), the gastroenterologist found a 
pathological mass in the prostate gland and they were referred to their family physi-
cians. Of the 134 patients who went to their family physician, 58 (43.3%) remained 
for observation and monitoring and 76 (56.7%) were referred to urologists for further 
examination. Three patients were diagnosed with prostate cancer. The total cost of 
the screening and follow-up was $25 per patient and the cost per a prostate cancer
detected was approximately $5000. CONCLUSIONS: Our screening model is appli-
cable, efﬁ cient, easy to implement and can be introduced with minimal investment of 
resources. Further studies are needed to examine the long-term cost-effectiveness of 
such a screening program.
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GAINS ASSOCIATED WITH CLINICAL EXAMS AND MAMMOGRAPHIC
SCREENING FOR WOMEN ABOVE 40 YEARS OF AGE
Calefﬁ  M1, Boscatti FHG2, Ribeiro RA1, Bedin Junior A1, Duarte Filho D1, Muranaka AH3, 
Weber B1
1Hospital Moinhos de Vento, Porto Alegre, RS, Brazil, 2Universidade de São Paulo, Sao Paulo, 
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OBJECTIVES: In Brazil, according to the National Cancer Institute (INCA, 2005), 
approximately 50% of all breast cancer (BC) diagnosis point to advanced cases at 
the time of ﬁ rst presentation (stages III and IV), which results in a maximal 5 
year survival rate of 36% for these women (The Susan G. Komen Breast Cancer 
Foundation). It is supposed that this mortality could be reduced through an improve-
ment of public breast health care to encourage early detection of breast lesions for
the population. Hence, the Associação Hospitalar Moinhos de Vento started a part-
nership with Health Secretary of Porto Alegre (capital of Rio Grande do Sul State) 
to perform a study to measure the impact of annual clinical examinations together
with mammography for underserved women over 40 years old. METHODS: A
total of 9,218 women aged between 40 and 69 year old, living in a delimited 
geographic area connected to 18 Health Care Units of Porto Alegre are being 
studied; BC risk factors are also being assessed. For these, yearly clinical examinations 
and screening mammograms are performed. The analysis is related to the ﬁ rst four
years of the project. Its results are compared against INCA epidemiologic data.
RESULTS: Among the searched universe, 50 women have been diagnosed for BC.
Comparing the cancer staging of these women at diagnosis with INCA data for the 
same region, we have: stage 0 (16% VS 6.7%), stage I (38% VS 20.6%), stage II 
(32% VS 45%), stage III (10% VS 20%) and stage IV (4% VS 7.7%), respectively.
CONCLUSIONS: The study showed that the annual screening associated with preven-
tive mammography for women above 40 year old increased their likelihood of an early 
diagnosis of BC, thus yielding them a better survival and cure prognostic. Therefore, 
the national adoption of this protocol could reduce the high mortality associated with 
this neoplasia.
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USING PREDICTIVE MODELS TO ANALYZE LUNG CANCER DATA
Tang G
University of Louisville, Louisville, KY, USA
OBJECTIVES: The purpose of this study is to examine the relationship between
patient outcomes and conditions of the patients undergoing different treatments for
lung cancer and to estimate the population burden, the cost of cancer, and to examine
treatment choice in clinical decision-making. METHODS: Lung Cancer data were 
extracted from the Medstat MarketScan Database based on ICD9 diagnosis codes.
